Bioavailability Study Comparing 2 Vamifeport Oral Formulations in Fasted Versus Fed State in Healthy Subjects

Inclusion Criteria: * Healthy participant. Healthy status defined by the Investigator. * A body weight between 50 and 100 kg inclusive at screening. * Non-smokers, or former smokers. * Both female and male participants must agree to comply with the birth control requirements for the study. * Ability to understand the requirements of the study and abide by the study restrictions, and agreement to return for the required assessments. Exclusion Criteria: * History of clinically significant gastrointestinal, cardiovascular, musculoskeletal, endocrine, neurological, hematological, psychiatric, renal, hepatic, bronchopulmonary, allergic or lipid metabolism disorders, cancer, or drug hypersensitivity. * Any clinically relevant abnormal 12-lead ECG finding during screening or prior to randomization. * A clinically relevant history of drug or alcohol misuse or abuse within 2 years prior to screening. * Positive qualitative or semi-quantitative test for drugs of abuse positive cotinine screen (used to detect recent nicotine use), or alcohol breath test at screening (Visit 1) or Study Day -1 (Visit 2). Use of any of these agents will be not permitted during study participation. * Strenuous physical exercise within the 1 week prior to Visit 2/Study Day -1 admission, and until completion of safety follow-up assessments are completed. * Female participants who are pregnant or breastfeeding. * Any concomitant medication (including herbal remedies and vitamins) taken within 2 weeks prior to Visit 2. * Concomitant use of hormonal contraceptives (contraception associated with inhibition of ovulation), which are metabolized through cytochrome P450 (CYP) 3A4. * Any other investigational drug. * Blood draw or blood donation of ≥20 to \<200 ml within 2 weeks, ≥200 to \<400 ml within 4 weeks, or ≥400 ml within 12 weeks (male) or within 16 weeks (female) prior to Visit 2.